Comments
Pharma major Dr Reddy’s Laboratories Ltd has on Tuesday announced the launch of Pregabalin capsules, a therapeutic equivalent generic version of Lyrica (Pregabalin) capsules approved by the U.S. Food and Drug Administration (USFDA).
Lyrica is a trademark of C.P. Pharmaceuticals International C.V. The Lyrica (Pregabalin) capsules brand had U.S. sales of approximately $5,462 million for the most recent twelve months ending in May 2019 according to IQVIA Health, Hyderabad-based company said in a release issued here.
Dr Reddy’s Pregabalin capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product. It is generally indicated for curing neuropathic pain, among others.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.